

John Morser received his Ph.D. from Warwick University (England) in Virology. After completing a post-doc in Helsinki (Finland), he returned to Warwick University to study interferon. John joined Codon, a small biotech in the San Francisco Bay Area, where he worked on fibrinolysis. After Codon was acquired by Schering, John was appointed head of cardiovascular research with a focus on thrombosis and hemostasis, and in particular, working on thrombomodulin and coagulation inhibitors. He spent 3 years in Kobe, Japan as deputy director of NihonSchering's regenerative medicine centre. Currently John is Senior Research Scientist in Hematology at Stanford University and Adjunct Professor at Mie University in Japan where he is studying the links between hemostasis and inflammation with emphasis on chemerin, osteopontin and CPB2 (TAFI).